Drug intelligence / Profile preview

schizochytrium microalga oil

Development stage
Unknown
Lead developer
Royal DSM
Administration
Oral
01

Overview

Schizochytrium microalga oil is an edible oil derived from microalgae of the genus Schizochytrium, produced via fermentation and extraction of the microalgal biomass[1][2]. The oil is exceptionally rich in the omega-3 fatty acid docosahexaenoic acid (DHA), typically comprising 40% or more of the total fatty acids, and may also contain other polyunsaturated fatty acids such as docosapentaenoic acid (DPA) and eicosapentaenoic acid (EPA)[1][2]. It is used primarily as a dietary supplement (not a pharmaceutical drug), most commonly for nutritional enrichment in infant formula, dietary supplements, and animal feed as a sustainable, plant-based alternative to fish oil[1][4][5][8]. The oil has a mixture of triglycerides and is sometimes stabilized with approved antioxidants[1]. Its primary biological function is as a source of DHA for human nutrition, where it serves to supplement or replace DHA from marine fish sources, supporting brain and visual development, especially in infants[8]. It may also have anti-inflammatory effects secondary to its fatty acid profile[3]. The oil is commonly regarded as safe for oral use, including in infants, and is generally recognized as safe (GRAS) by regulatory authorities in several regions[8]. It is not used as a pharmaceutical therapy but rather as a functional food or dietary supplement.

Brand names
life'sDHADHASCO-S
Other names
schizochytrium oilalgal oil (from schizochytrium)schizochytrium sp. oil
02

Targets

ADGRF1PPARG (Peroxisome proliferator-activated receptor gamma)RXRA (Retinoid X receptor alpha)PPARA (Peroxisome proliferator-activated receptor alpha)

Beyond the preview

Go deeper on schizochytrium microalga oil.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on schizochytrium microalga oil.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call